Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s mobile device integrated auto-injector platform, including its intellectual property portfolio and related physical assets. The acquired platform represents nearly a decade of award-winning innovation and product development at Alerje.

“This platform is technically sound, IP secured, and commercially relevant,” said Elizabeth Reczek, PhD, CEO of Sempresto. “With Sempresto’s expertise, capital, and clarity of purpose, we are well positioned to accelerate final development and deliver this life saving innovation to patients who need it most.”

“This deal represents both a capstone and a beginning,” said Javier Evelyn, Founder and CEO of Alerje. “Sempresto is the right team to bring this device across the finish line, with a now dominant global IP position and deep commercialization expertise. Meanwhile, Alerje is entering an exciting new phase, doubling down on the software, diagnostics, and AI that will power food allergy care at scale.”

This strategic transaction strengthens Sempresto’s leadership in cellphone mounted drug delivery systems while enabling Alerje to expand its focus on AI enabled software solutions for food allergy management. The agreement reflects both companies’ commitment to advancing care for patients at risk of anaphylaxis while focusing on their respective core strengths.

About Sempresto, Inc.

Sempresto is led by an experienced team of life science and medical technology professionals, many with firsthand experience managing severe allergies. The company’s mission - “Always There, Always Connected” - drives its development of innovative solutions that ensure immediate access to life-saving medicines. Sempresto’s flagship product, a smartphone-integrated epinephrine autoinjector, represents a transformative leap forward in preparedness for severe allergy sufferers and other acute conditions.

About Alerje, Inc.

Alerje delivers collaborative care for food allergies, connecting families and allergists through its FAIT digital health app to manage treatment, testing, and daily monitoring in one place. The AI enabled platform helps improve communication and enable unrealized revenue for allergy clinics. With food allergies affecting over 220 million people and the treatment market projected to reach $11.3B by 2030, Alerje is redefining how allergy care is delivered earning support and recognition from the National Science Foundation, the Department of Defense, Google for Startups, and CES.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251204523180/en/